Ken Griffin’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-22,493
| Closed | -$651K | – | 13754 |
|
|
2025
Q4 | $651K | Buy |
+22,493
| New | +$427K | ﹤0.01% | 8379 |
|
|
2025
Q1 | – | Sell |
-16,854
| Closed | -$260K | – | 15192 |
|
|
2024
Q4 | $603K | Sell |
16,854
-159,608
| -90% | -$8.26M | ﹤0.01% | 8153 |
|
|
2024
Q3 | $8.34M | Buy |
176,462
+66,718
| +61% | +$2.94M | ﹤0.01% | 3189 |
|
|
2024
Q2 | $5.51M | Sell |
109,744
-28,615
| -21% | -$2.07M | ﹤0.01% | 3598 |
|
|
2024
Q1 | $15.5M | Buy |
138,359
+61,282
| +80% | +$6.09M | ﹤0.01% | 2359 |
|
|
2023
Q4 | $4.47M | Buy |
77,077
+12,488
| +19% | +$502K | ﹤0.01% | 3959 |
|
|
2023
Q3 | $2.05M | Buy |
64,589
+64,586
| +2,152,867% | +$3.07M | ﹤0.01% | 5151 |
|
|
2023
Q2 | $250 | Sell |
3
-4,503
| -100% | -$659K | ﹤0.01% | 14169 |
|
|
2023
Q1 | $463K | Sell |
4,506
-20,517
| -82% | -$2.88M | ﹤0.01% | 8476 |
|
|
2022
Q4 | $3.67M | Buy |
25,023
+17,947
| +254% | +$3.03M | ﹤0.01% | 4406 |
|
|
2022
Q3 | $1.2M | Sell |
7,076
-6,981
| -50% | -$1.13M | ﹤0.01% | 6602 |
|
|
2022
Q2 | $1.62M | Sell |
14,057
-13,411
| -49% | -$1.26M | ﹤0.01% | 5985 |
|
|
2022
Q1 | $2.74M | Buy |
27,468
+15,128
| +123% | +$1.77M | ﹤0.01% | 5395 |
|
|
2021
Q4 | $1.92M | Buy |
12,340
+10,466
| +558% | +$2.04M | ﹤0.01% | 6343 |
|
|
2021
Q3 | $442K | Sell |
1,874
-21,691
| -92% | -$6.34M | ﹤0.01% | 10182 |
|
|
2021
Q2 | $8M | Buy |
23,565
+2,029
| +9% | +$768K | ﹤0.01% | 3483 |
|
|
2021
Q1 | $8.71M | Sell |
21,536
-56,665
| -72% | -$27.5M | ﹤0.01% | 3191 |
|
|
2020
Q4 | $52M | Buy |
78,201
+61,473
| +367% | +$34.2M | 0.01% | 923 |
|
|
2020
Q3 | $7.79M | Sell |
16,728
-7,200
| -30% | -$3.64M | ﹤0.01% | 2597 |
|
|
2020
Q2 | $14M | Buy |
23,928
+5,481
| +30% | +$1.87M | 0.01% | 1846 |
|
|
2020
Q1 | $2.69M | Buy |
18,447
+9,643
| +110% | +$1.69M | ﹤0.01% | 3649 |
|
|
2019
Q4 | $1.26M | Buy |
8,804
+5,077
| +136% | +$371K | ﹤0.01% | 5183 |
|
|
2019
Q3 | $147K | Buy |
3,727
+502
| +16% | +$36.5K | ﹤0.01% | 8312 |
|
|
2019
Q2 | $326K | Buy |
3,225
+1,363
| +73% | +$161K | ﹤0.01% | 7451 |
|
|
2019
Q1 | $245K | Sell |
1,862
-100
| -5% | -$12.6K | ﹤0.01% | 7908 |
|
|
2018
Q4 | $200K | Buy |
+1,962
| New | +$310K | ﹤0.01% | 7860 |
|
|
2017
Q3 | – | Sell |
-513
| Closed | -$179K | – | 7838 |
|
|
2017
Q2 | $179K | Buy |
+513
| New | +$177K | ﹤0.01% | 6633 |
|
Other funds holding MRSN
Ken Griffin's MRSN Position: Q1 2026 in Review
Ken Griffin sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 22,493 shares — an estimated $651K sold.
Ken Griffin first reported a position in MRSN in Q2 2017 and held it in 27 quarters. The position peaked at $52M in Q4 2020. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- Ken Griffin reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- Ken Griffin sold 22,493 Mersana Therapeutics shares in Q1 2026, an estimated $651K.
- Ken Griffin first reported a position in Mersana Therapeutics in Q2 2017 and held it in 27 quarters.
- Ken Griffin's Mersana Therapeutics position peaked at $52M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.